Brand Name

Tivicay

Generic Name
Dolutegravir
View Brand Information
FDA approval date: August 13, 2013
Classification: Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor
Form: Tablet

What is Tivicay (Dolutegravir)?

TIVICAY and TIVICAY PD are indicated in combination with other antiretroviral agents for the treatment of HIV‑1 infection in adults and in pediatric patients (treatment-naïve or -experienced but integrase strand transfer inhibitor -naïve) aged at least 4 weeks and weighing at least 3 kg [see Microbiology ( 1.

Approved To Treat

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study

Background: People with HIV take drugs to keep the amount of virus in their body low. One type of these drugs, called integrase strand transfer inhibitors (INSTIs), can cause weight gain over time. Weight gain can cause diabetes, heart disease, and other serious issues. Researchers want to understand how INSTIs cause weight changes.

Co-benefits of Co-delivery of Long-acting Antiretrovirals and Contraceptives

Summary: The study investigators are conducting foundational pharmacokinetic (PK) and qualitative studies, among 15-24 years old (inclusive) adolescent girls and young women living with HIV (AGYWLHIV) already on oral antiretroviral therapy (ART) and virally suppressed, leading up to a hybrid type I effectiveness-implementation trial randomizing individual AGYWLHIV to receive long-acting (LA) injectable cab...

Very Early Intensive Treatment of Infants Living With HIV to Achieve HIV Remission: A Phase I/II Proof of Concept Study

Summary: The study will explore the effects of early intensive antiretroviral therapy (ART) with or without a broadly neutralizing antibody (bNAb) on achieving HIV remission (HIV RNA below the limit of detection of the assay) among infants living with HIV.